Insights
Search Results
Client Highlights
6.05.26
Firm Advises Ona Therapeutics on IP Matters Related to $86.6 Million Series B
On June 4, 2026, Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV, and Ysios Capital. Wilson Sonsini Goodrich & Rosati advised Ona Therapeutics on IP matters related to the transaction.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
News Articles
6.05.26
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 List of Next-Generation Lawyers
Ten Wilson Sonsini attorneys have been recognized in the 2026 edition of Lawdragon 500 X – The Next Generation. Individuals listed in the guide are “the future of the law” and are recognized for their accomplishments in their career thus far.
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.16.26
Wilson Sonsini Advises Terremoto on IP Matters Related to $108 Million Series C
On April 15, 2026, Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Terremoto on IP matters related to the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Centessa on IP Matters Related to Acquisition by Lilly
On March 31, 2026, Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Eli Lilly and Company (Lilly), an American multinational pharmaceutical company, to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and the CVR represents an additional potential aggregate equity value of approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati advised Centessa in IP matters related to the transaction.
Client Highlights
3.12.26
Firm Advises Day One on IP Matters Related to $2.5 Billion Acquisition by Servier
On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises Soley Therapeutics on $200 Million Series C Financing
On January 7, 2026, Soley Therapeutics, a science-first, tech-enabled drug discovery and development company, announced a $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into the clinic. New investors in this round included Surveyor Capital as primary investor, joined by HRTG Partners, RWN Management, and others. Existing Soley investors, including Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investments® LP, and other undisclosed investors also participated. Wilson Sonsini Goodrich & Rosati advised Soley on the transaction.
The proceeds from the Series C will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, as well as continued platform scale-up.
The proceeds from the Series C will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, as well as continued platform scale-up.
Client Highlights
12.17.25
Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $55 Million Series B Financing
On December 16, 2025, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing highly selective small molecule therapeutics that restore cellular metabolic quality control, announced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. Proceeds from the financing will support the advancement of AV078 into a Phase 2 proof-of-concept study in participants with TSC-refractory epilepsy. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction.
Client Highlights
11.19.25
Wilson Sonsini Advises Day One on IP Matters Related to Acquisition of Mersana
On November 13, 2025, Day One Biopharmaceuticals (Day One), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced it has signed a definitive merger agreement to acquire Mersana Therapeutics (Mersana). Wilson Sonsini Goodrich & Rosati advised Day One on IP due diligence related to the transaction.
News Articles
7.11.25
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
Client Highlights
4.02.25
Wilson Sonsini Advises Edgewise Therapeutics on $200 Million Underwritten Offering
On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
Client Highlights
4.04.24
Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $50 Million Series A
On March 28, 2024, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, announced it has completed a $50 million Series A financing extension, led by Hevolution. Existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture also participated in the Series A round. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction, and manages Aeovian’s patent portfolio strategy.
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.